Juan Zamora
Laboratorio Médico Polanco
View from the Top

LMP Seeks to Assure Better Care, Prevention

By Miriam Bello | Mon, 09/27/2021 - 09:34

Q: As the new director of Laboratorio Médico Polanco (LMP), how are you moving the company toward a preventive healthcare model?

A: Preventive healthcare is something we are learning as a society. During the pandemic, the world started to become aware of the importance of prevention. A true culture of prevention where everyone lives healthier lives is yet to come. Health is an accumulation of decisions in our lives.

Laboratories are obligated to offer solutions that accompany patients through all aspects of their health. We must act as allies to help empower patients to take proactive control of their health.

Q: Austerity is among company’s values. How have you balanced that with investment in innovation?

A: Austerity is not necessarily reflected in technology, services or the core of our business. It is reflected in us, in the type of offices we have, where they are located, the cars we drive and so on. This allows us as a company to invest in everything that adds value to be able to offer the best diagnosis to patients.

We have invested significant sums to guarantee the quality of the diagnostic service, both in the laboratory and imaging. This year, we will replace imaging equipment in around 60 percent of our business units. We also invested in the installation of a temporary laboratory to offer diagnostic services in CitiBanamex's temporary hospital. Other important investments have been made in training our personnel and creating jobs.

Q: What are your priorities at the head of LMP?

A: Many of our plans have changed radically. Although these are temporary changes, many studies have been put on hold. Also, we stopped providing certain studies because we had to concentrate on COVID-19-related studies. There has definitely been a larger demand for the latter than there has been for the other studies we performed, especially as patients interrupted their continuity of care. We are now seeing a return to that continuity. We are not only seeing patients resume the care they paused; we are also seeing patients embrace a preventive approach to their health through check-ups.

Our promotional campaigns in May and June are completely focused on prevention. In May, we will focus on women's health and in June, the focus will be on younger people who might not have been health conscious before. We are trying to reach young people through exercise and fitness check-ups in alliance with representatives of the team that will participate in the Japan Paralympics. With this campaign, we want to invite the population to take care of their health through prevention.

Q: What trends have you identified that could benefit from new diagnostic solutions?

A: We are developing tests for geriatric patients through a new branch. Another relevant area is women's health because we have seen that women act as health promoters within their families. This dynamic has existed for a long time but it was strengthened during the pandemic. Another important topic for prevention is diabetes. We are working to identify patients who are predisposed to develop insulin resistance or diabetes.

We are also focusing on the digitalization of services, a trend that had been growing before the pandemic but which has skyrocketed since it started. We are developing appropriate solutions and technologies so patients can stay home. The objective is to offer a home lab. We are performing home-based laboratory and imaging tests and, gradually, we are going to increase the services we offer. The goal is to have an app that facilitates this process from a distance and meets the needs of the patient.

Q: How is LMP upgrading the services it offers to other companies? What added value do you offer to these clients?

A: Our B2B services focus on two important business lines. The first is serving companies that are relevant in their different segments. During the pandemic, we helped them keep their operations in the best possible condition. We also process many samples from other laboratories and hospitals.

We have also realized that we can expand our range of services and accelerate diagnostic capacity through innovation, technology and process efficiency. This will allow us to reach more companies and also the medical sector. For example, we are setting up a laboratory inside the Guadalajara airport for PCR testing, avoiding the need to take samples to an external processing center. These kinds of opportunities have allowed us to offer a better, faster and more efficient service.

Q: What are your perspectives post-COVID, especially regarding chronic and cardiometabolic disease control?

A: One of our main priorities is vaccination. The infection curve is flattening and in the coming months, after more people are vaccinated, we want to provide specific tests to quantify immunity levels. In the meantime, although we are pleased that the curve is flattening, we are still prepared for a third wave.

Regarding prevention, we are developing early diagnostic tests for insulin resistance. In June, we will start new check-ups, which will include consultations on obesity, impedanciometry and nutritional care. We have also been offering multiple webinars for patients and physicians to better educate the population. At the same line, we are organizing a congress for the medical community to present this information and our own research. This will allow physicians to provide better care.


Laboratorio Médico Polanco has 29 years of experience providing laboratory and X-ray services. Its portfolio now includes clinical analysis, parasitology, immunology, hematology, microbiology, clinical chemistry and cytology.

Miriam Bello Miriam Bello Journalist and Industry Analyst